PCM
SRPT icon

Potomac Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Potomac Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-21,100
Closed -$445K – 81
2014
Q3 		$445K Sell
21,100
-1,000
-5% -$22.6K 0.49% 55
2014
Q2 		$658K Hold
22,100
– – 0.52% 43
2014
Q1 		$531K Buy
22,100
+9,000
+69% +$229K 0.45% 42
2013
Q4 		$267K Buy
+13,100
New +$389K 0.23% 55

Other funds holding SRPT

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Potomac Capital Management's SRPT Position: Q4 2014 in Review

Potomac Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2014, closing a stake of 21,100 shares — an estimated $445K sold.

Potomac Capital Management first reported a position in SRPT in Q4 2013 and held it in 4 quarters. The position peaked at $658K in Q2 2014. 120 funds tracked by Wall St. Rank hold SRPT as of Q4 2014.

  • Potomac Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Potomac Capital Management sold 21,100 Sarepta Therapeutics shares in Q4 2014, an estimated $445K.
  • Potomac Capital Management first reported a position in Sarepta Therapeutics in Q4 2013 and held it in 4 quarters.
  • Potomac Capital Management's Sarepta Therapeutics position peaked at $658K in Q2 2014.
  • 120 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2014.

Based on Potomac Capital Management's 13F filing for Q4 2014, filed 11 Feb 2015.